Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $52
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum maintains a Buy rating on Rocket Pharmaceuticals (NASDAQ:RCKT) but lowers the price target from $53 to $52.

June 28, 2024 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Gil Blum maintains a Buy rating on Rocket Pharmaceuticals but lowers the price target from $53 to $52.
The analyst's decision to maintain a Buy rating suggests continued confidence in Rocket Pharmaceuticals' prospects. However, the slight reduction in the price target indicates a minor adjustment in expectations. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100